Cytoplasmic cd133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3432-3440

  Jao, Shu Wen ^a   Chen, Su Feng ^b   Lin, Yaoh Shiang ^a   Chang, Yun Ching ^a,c   Lee, Tsai Yu ^a   Wu, Chang Chieh ^a   Jin, Jong Shiaw ^d   Nieh, Shin ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR REGRESSION;

ADENOCARCINOMA; AGED; ANTIGENS, CD; CHEMORADIOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; CYTOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PEPTIDES; PROGNOSIS; RECTAL NEOPLASMS; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC;

EID: 85027925784     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2394-3     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: Recent data from the laboratory and clinic. Mol Ther. 2009;17:219-30.
3. Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: A 2006 update. World J Gastroenterol. 2006;12:3186-95. (Pubitemid 43881342)
4. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-36.
5. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-96. (Pubitemid 46211512)
6. van den Brink M, Stiggelbout AM, van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22:3958-64. (Pubitemid 41079878)
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11. (Pubitemid 33041634)
8. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895-902. (Pubitemid 37500174)
9. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84. (Pubitemid 40488633)
10. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004;23:7178-87. (Pubitemid 39382152)
11. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002-12. (Pubitemid 28007217)
12. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10. (Pubitemid 46067310)
13. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon cancer-initiating cells. Nature. 2007;445:111-5. (Pubitemid 46067311)
14. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1:389-402. (Pubitemid 47506537)
15. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285-9.
16. Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007;110:534-42. (Pubitemid 47106141)
17. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751-60.
18. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133? and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111-20. (Pubitemid 351872330)
19. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009;219:427-34.
20. Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A. Expression of the ''stem cell marker'' CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008;8:48.
21. Saigusa S, Tanaka K, Toiyama Y, et al. Immunohistochemical features of CD133 expression: Association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep. 2010;24:345-50.
22. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16:3488-98.
23. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23;8688-96. (Pubitemid 46211512)
24. Chen SF, Yang SF, Li JW, et al. Expression of fascin in oral and oropharyngeal squamous cell carcinomas has prognostic significance - a tissue microarray study of 129 cases. Histopathology. 2007;51:173-83. (Pubitemid 47083998)
25. Crawford NP, Colliver DW, Galandiuk S. Tumor markers and colorectal cancer: Utility in management. J Surg Oncol. 2003;84; 239-48. (Pubitemid 37484790)
26. Hongo K, Tanaka J, Tsuno NH, et al. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(?) cells, dependent on the b1- integrin signaling. J Surg Res. 2011. doi:10.1016/j.jss.2011. 03.076.
27. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009;15: 2258-64.
28. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: A clinicopathological study. Cancer Sci. 2008;99: 1578-83.
29. Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 2004;104:2332-8. (Pubitemid 39331830)
30. Sanchez-Madrid F, del Pozo MA. Leukocyte polarization in cell migration and immune interactions. EMBO J. 1999;18:501-11. (Pubitemid 29057235)
31. Lajtha LG. Stem cell concepts. Nouv Rev Fr Hematol. 1979;21: 59-65. (Pubitemid 9156542)
32. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133? tumour cells and clinical outcome in rectal cancer. Histopathology. 2009;55:284-93.
33. Shia J, McManus M, Guillem JG, et al. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am J Surg Pathol. 2011;35:127-34.
34. Casado E, García VM, Sánchez JJ, et al. A Combined strategy of SAGE and quantitative PCR cancer chemoradiotherapy response and outcome in rectal provides a 13-gene signature that predicts preoperative. Clin Cancer Res. 2011;17:4145-54.